Search

Your search keyword '"Lynch M"' showing total 17 results
Start Over Author "Lynch M" Journal annals of oncology
17 results on '"Lynch M"'

1. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Author

Swain, S.M., Ewer, M.S., Viale, G., Delaloge, S., Ferrero, J.-M., Verrill, M., Colomer, R., Vieira, C., Werner, T.L., Douthwaite, H., Bradley, D., Waldron-Lynch, M., Kiermaier, A., Eng-Wong, J., and Dang, C.

Published
2018
Full Text
View/download PDF

5. 1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study

Author

Vansteenkiste, J.F., primary, Smit, E.F., additional, Groen, H.J.M., additional, Garon, E.B., additional, Heist, R.S., additional, Hida, T., additional, Nishio, M., additional, Kokowski, K., additional, Grohe, C., additional, Reguart, N., additional, Mansfield, A.S., additional, Robeva, A., additional, Ghebremariam, S., additional, Waldron-Lynch, M., additional, Akimov, M., additional, Nwana, N., additional, Giovannini, M., additional, and Wolf, J., additional

Published
2020
Full Text
View/download PDF

7. Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Author

Wolf, J., primary, Seto, T., additional, Han, J.-Y., additional, Reguart, N., additional, Garon, E.B., additional, Groen, H.J.M., additional, Tan, D.S., additional, Hida, T., additional, de Jonge, M.J.A., additional, Orlov, S.V., additional, Smit, E.F., additional, Souquet, P.-J., additional, Vansteenkiste, J.F., additional, Giovannini, M., additional, Le Mouhaer, S., additional, Robeva, A., additional, Waldron-Lynch, M., additional, and Heist, R.S., additional

Published
2018
Full Text
View/download PDF

9. Nivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141

Author

Licitra, L., primary, Ferris, R.L., additional, Blumenschein, G., additional, Harrington, K.J., additional, Guigay, J., additional, Kasper, S., additional, Saba, N.F., additional, Haddad, R., additional, Kiyota, N., additional, Monga, M., additional, Lynch, M., additional, Li, L., additional, Gillison, M.L., additional, and Fayette, J., additional

Published
2017
Full Text
View/download PDF

10. Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes

Author

Haddad, R., primary, Blumenschein, G., additional, Fayette, J., additional, Guigay, J., additional, Colevas, A.D., additional, Licitra, L., additional, Kasper, S., additional, Vokes, E.E., additional, Worden, F., additional, Saba, N.F., additional, Tahara, M., additional, Concha-Benavente, F., additional, Monga, M., additional, Lynch, M., additional, Li, L., additional, Shaw, J.W., additional, Gillison, M.L., additional, Harrington, K.J., additional, and Ferris, R.L., additional

Published
2017
Full Text
View/download PDF

11. 360O_PR Efficacy and safety of nivolumab for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in Asia: CheckMate 141 subgroup analysis

Author

Hasegawa, Y., primary, Kiyota, N., additional, Takahashi, S., additional, Yokota, T., additional, Yen, C-J., additional, Iwae, S., additional, Shimizu, Y., additional, Hong, R-L., additional, Goto, M., additional, Namba, Y., additional, Ferris, R.L., additional, Monga, M., additional, Lynch, M., additional, Hagihara, S., additional, and Tahara, M., additional

Published
2016
Full Text
View/download PDF

12. LBA52 - Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Author

Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E.B., Groen, H.J.M., Tan, D.S., Hida, T., de Jonge, M.J.A., Orlov, S.V., Smit, E.F., Souquet, P.-J., Vansteenkiste, J.F., Giovannini, M., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M., and Heist, R.S.

Published
2018
Full Text
View/download PDF

14. 1043O - Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes

Author

Haddad, R., Blumenschein, G., Jr, Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., Kasper, S., Vokes, E.E., Worden, F., Saba, N.F., Tahara, M., Concha-Benavente, F., Monga, M., Lynch, M., Li, L., Shaw, J.W., Gillison, M.L., Harrington, K.J., and Ferris, R.L.

Published
2017
Full Text
View/download PDF

17. CORRIGENDUM.

Author

Swain, S M, Schneeweiss, A, Gianni, L, Gao, J J, Stein, A, Waldron-Lynch, M, Heeson, S, Beattie, M S, Yoo, B, and Cortes, J

Subjects
*DIARRHEA, *HORMONE receptor positive breast cancer, *HER2 gene
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results